Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 2800 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/03/22
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 11/23/11
End: 03/19/26
Due: 03/19/27
Phase: N/A
Priority: Normal
Start: 07/30/12
End: 03/19/26
Due: 03/19/27
Phase: N/A
Priority: Normal
Start: 12/31/00
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 06/30/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/25/11
End: 03/19/26
Due: 03/19/27
Phase: N/A
Priority: Normal
Start: 04/19/11
End: 11/19/20
Due: 11/19/21
Phase: N/A
Priority: Normal
Start: 08/31/06
End: 09/30/10
Due: 09/30/11
Phase: N/A
Priority: Normal
Start: 05/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 08/20/09
End: 04/11/19
Due: 04/11/20
Phase: N/A
Priority: Normal
Start: 10/31/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/16/15
End: 07/02/18
Due: 07/02/19
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase: N/A
Priority: Normal
Start: 12/31/05
End: 09/30/10
Due: 09/30/11
Phase: N/A
Priority: Normal
Start: 11/21/14
End: 03/07/17
Due: 03/07/18
Phase: N/A
Priority: Normal
Start: 12/31/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/10/04
End: 08/05/08
Due: 08/05/09
Phase: N/A
Priority: Normal
Start: 04/03/09
End: 01/16/14
Due: 01/16/15
Phase: N/A
Priority: Normal
Start: 02/29/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/19/23
End: 12/01/28
Due: 12/01/29
Phase: N/A
Priority: Normal
Start: 08/28/17
End: 05/30/27
Due: 05/30/28
Phase: N/A
Priority: Normal
Start: 07/28/10
End: 11/18/11
Due: 11/18/12
Phase: N/A
Priority: Normal
Start: 06/30/00
End: 08/31/07
Due: 08/31/08
Phase: N/A
Priority: Normal
Start: 06/30/97
End: 03/31/00
Due: 03/31/01
Phase: N/A
Priority: Normal
Start: 01/05/12
End: 09/01/16
Due: 09/01/17